Schedules of controlled substances; production quotas: Proposed 2000 aggregate,
[Federal Register: July 19, 2000 (Volume 65, Number 139)]
[Notices]
[Page 44836-44838]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr19jy00-117]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[DEA #186R]
Controlled Substances: Proposed Revised Aggregate Production Quotas for 2000
AGENCY: Drug Enforcement Administration (DEA), Justice.
ACTION: Notice of proposed revised 2000 aggregate production quotas.
SUMMARY: This notice proposes revised 2000 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act (CSA).
DATES: Comments or objections must be received on or before August 18, 2000.
ADDRESSES: Send comments or objectives to the Deputy Administrator, Drug Enforcement Administration, Washington, D.C. 20537, Attn.: DEA Federal Register Representative (CCR).
FOR FURTHER INFORMATION CONTACT: Frank L. Sapienza, Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration, Washington, D.C. 20537, Telephone: (202) 307-7183.
SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations. The Administrator, in turn, has redelegated this function to the Deputy Administrator of the DEA pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations.
On February 10, 2000, DEA published a notice of established initial 2000 aggregate production quotas for certain controlled substances in Schedules I and II (65 FR 6635). This notice stipulated that the Deputy Administrator of the DEA would adjust the quotas in early 2000 as provided for in Section 1303 of Title 21 of the Code of Federal Regulations.
The proposed revised 2000 aggregate production quotes represent those quantities of controlled substances in Schedules I and II that may be produced in the United States in 2000 to provide adequate supplies of each substance for: the estimated medical, scientific, research, and industrial needs of the United States; lawful export requirements; and the establishment and maintenance of reserve stocks. These quotas do not include imports of controlled substances for use in industrial processes.
The proposed revisions are based on a review of 1999 year-end inventories, 1999 disposition data submitted by quota applicants, estimates of the medical needs of the United States, and other information available to the DEA.
In addition, in a final rule published in the Federal Register on March 13, 2000 (65 FR 13235) gamma-hydroxybutyric acid (GHB) and its salts, isomers, and salts of isomers was placed into Schedule I of the CSA. Applications for quota for this substance were submitted and the aggregate production quota for gamma-hydroxybutyric acid is proposed as listed below.
Therefore, under the authority vested in the Attorney General by Section 306 of the CSA of 1970 (21 U.S.C. 826), delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations, and redelegated to the Deputy Administrator pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations, the Administrator hereby proposes the following revised 2000 aggregate production quotas for the following controlled substances, expressed in grams of anhydrous acid or base:
Previously established Proposed Basic class
initial 2000 revised 2000 quotas
quotas
SCHEDULE I
2,5-Dimethoxyamphetamine................ 10,001,000 10,501,000 2,5-Dimethoxy-4-ethylamphetamine (DOET).
2
2 3-Methylfentanyl........................
14
14 3-Methylthiofentanyl....................
2
2 3,4-Methylenedioxyamphetamine (MDA).....
20
20 3,4-Methylenedioxy-N-ethylamphetamine
30
30 (MDEA)................................. 3,4-Methylenedioxymethamphetamine (MDMA)
20
20 3,4, 5-Trimethoxyamphetamine............
2
2 4-Bromo-2,5-Dimethoxyamphetamine (DOB)..
2
2 4-Bromo-2,5-Dimethoxyphenethylamine (2-
2
2 CB).................................... 4-Methoxyamphetamine....................
201,000
201,000 4-Methylaminorex........................
3
3 4-Methyl-2,5-Dimethoxyamphetamine (DOM).
2
2 5-Methoxy-3,4-Methylenedioxyamphetamine.
2
2 Acetyl-alpha-methylfentanyl.............
2
2 Acetyldihydrocodeine....................
2
2 Acetylmethadol..........................
7
7 Allylprodine............................
2
2 Alphacetylmethadol......................
7
7 Alpha-ethyltryptamine...................
2
2 Alphameprodine..........................
2
2 Alphamethadol...........................
2
2 Alpha-methylfentanyl....................
2
2 Alpha-methylthiofentanyl................
2
2 Aminorex................................
7
7 Benzylmorphine..........................
2
2 Betacetylmethadol.......................
2
2 Beta-hydroxy-3-methylfentanyl...........
2
2
[[Page 44837]]
Beta-hydroxyfentanyl....................
2
2 Betameprodine...........................
2
2 Betamethadol............................
2
2 Betaprodine.............................
2
2 Bufotenine..............................
2
2 Cathinone...............................
9
9 Codeine-N-oxide.........................
2
2 Diethyltryptamine.......................
2
2 Difenoxin...............................
10,000
10,000 Dihydromorphine.........................
508,000
508,000 Dimethyltryptamine......................
3
3 Gamma-hydroxybutyric acid............... .............. 15,000,000 Heroin..................................
2
2 Hydroxypethidine........................
2
2 Lysergic acid diethylamide (LSD)........
38
63 Mescaline...............................
7
7 Methaqualone............................
17
17 Methcathinone...........................
9
9 Morphine-N-oxide........................
2
2 N,N-Dimethylamphetamine.................
7
7 N-Ethyl-1-Phenylcyclohexylamine (PCE)...
5
5 N-Ethylamphetamine......................
7
7 N-Hydroxy-3,4-Methylenedioxyamphetamine.
2
2 Noracymethadol..........................
2
2 Norlevorphanol..........................
2
2 Normethadone............................
7
7 Normorphine.............................
7
7 Para-fluorofentanyl.....................
2
2 Pholcodine..............................
2
2 Propiram................................
415,000
415,000 Psilocybin..............................
2
2 Psilocyn................................
2
2 Tetrahydrocannabinols...................
101,000
115,000 Thiofentanyl............................
2
2 Trimeperidine...........................
2
2
SCHEDULE II
1-Phenylcyclohexylamine.................
12
12 1-Piperidiocyclohexanecarbonitrile (PCC)
10
10 Alfentanil..............................
8,000
8,000 Alphaprodine............................
2
2 Amobarbital.............................
12
12 Amphetamine............................. 9,007,000 6,491,000 Cocaine.................................
251,000
251,000 Codeine (for sale)...................... 54,504,000 43,248,000 Codeine (for conversion)................ 52,384,000 52,384,000 Dextropropoxyphene...................... 114,078,000 121,017,000 Dihydrocodeine..........................
268,000
133,000 Diphenoxylate...........................
931,000
931,000 Ecgonine................................
36,000
36,000 Ethylmorphine...........................
12
12 Fentanyl................................
300,000
300,000 Glutethimide............................
2
2 Hydrocodone (for sale).................. 20,208,000 21,417,000 Hydrocodone (for conversion)............ 20,700,000 20,700,000 Hydromorphone........................... 1,239,000 1,239,000 Isomethadone............................
12
12 Levo-alphacetylmethadol (LAAM)..........
201,000
12 Levomethorphan..........................
2
2 Levorphanol.............................
27,000
27,000 Meperidine.............................. 11,335,000 9,870,000 Metazocine..............................
1
1 Methadone (for sale).................... 8,347,000 8,347,000 Methadone (for conversion)..............
600,000
0 Methadone Intermediate.................. 9,503,000 9,503,000 Methamphetamine......................... 2,049,000 1,984,000
[750,000 grams of levo- desoxyephedrine for use in a non- controlled, non-prescription product; 1,225,000 grams for methamphetamine for conversion to a Schedule III product; and 9,000 grams for methamphetamine (for sale)] Methylphenidate......................... 14,957,000 14,957,000 Morphine (for sale)..................... 14,706,000 14,706,000
[[Page 44838]]
Morphine (for conversion)............... 97,160,000 97,410,000 Nabilone................................
2
2 Noroxymorphone (for sale)...............
25,000
25,000 Noroxymorphone (for conversion)......... 3,813,000 3,813,000 Opium...................................
720,000
720,000 Oxycodone (for sale).................... 29,826,000 32,575,000 Oxycodone (for conversion)..............
271,000 1,389,000 Oxymorphone.............................
166,000
477,000 Pentobarbital........................... 22,037,000 22,037,000 Phencyclidine...........................
41
41 Phenmetrazine...........................
2
2 Phenylacetone...........................
10
10 Secobarbital............................
22
22 Sufentanil..............................
1,700
1,700 Thebaine................................ 41,300,000 45,444,000
The Administrator further proposes that aggregate production quotas for all other Schedules I and II controlled substances included in sections 1308.11 and 1308.12 of Title 21 of the Code of Federal Regulations remain at zero.
All interested persons are invited to submit their comments and objections in writing regarding this proposal. A person may object to or comment on the proposal relating to any of the above-mentioned substances without filing comments or objections regarding the others. If a person believes that one or more of these issues warrant a hearing, the individual should so state and summarize the reasons for this belief.
In the event that comments or objections to this proposal raise one or more issues which the Administrator finds warrant a hearing, the Administrator shall order a public hearing by notice in the Federal Register, summarizing the issues to be heard and setting the time for the hearing as per 21 CFR 1303.13(c) and 1303.32.
The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. This action has been analyzed in accordance with the principles and criteria contained in Executive Order 13132, and it has been determined that this matter does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.
The Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601 et seq. The establishment of aggregate production quotas for Schedules I and II controlled substances is mandated by law and by international treaty obligations. Aggregate production quotas apply to approximately 200 DEA registered bulk and dosage form manufacturers of Schedules I and II controlled substances. The quotas are necessary to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and the establishment and maintenance of reserve stocks. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Administrator has determined that this action does not require a regulatory flexibility analysis.
Dated: July 12, 2000. Donnie R. Marshall, Administrator.
[FR Doc. 00-18148Filed7-18-00; 8:45 am]
BILLING CODE 4410-09-M
